Esperion
Cardiometabolic Therapeutics · Prescription Drugs

Esperion: Funding & valuation

Esperion: 0 money records, each linked to its source.

Data updated Nov 22, 2026 · Back to the company report

Financials

Revenue of $403.1M in 2025. +21.3% on the year before. Net income −$22.7M.

$403.1MRevenue2025 · +21.3%
−$22.7MNet income2025 · +56.2%
Revenue by yearas filed, with the net income
2025$403.1Mnet income −$22.7M
2024$332.3Mnet income −$51.7M
2023$116.3Mnet income −$209.2M
2022$75.5Mnet income −$233.7M
2021$78.4Mnet income −$269.1M
2020$227.5Mnet income −$143.6M
2019$148.4Mnet income −$97.2M
2018$0net income −$201.8M
Sources: SEC

Money

Esperion: 0 money records, each linked to its source.

Revenue as statedrun rates and months as the company or the press states them; filed results are in Financials
Revenue 2024 (Fastest Growing Companies The Americas 2026)
Jan 2024
$332.3M
Revenue 2021 (Fastest Growing Companies The Americas 2026)
Jan 2021
$78.4M
Growth rankingsthe yearly lists of the fastest growing companies
Fastest Growing Companies The Americas 2026
61.8% a year, 2021–2024 · revenue $332.3M in 2024 · 304 employees
#88
Every row links its own source. A flow two sources state counts once; a figure a source does not state reads "not stated".